NEW YORK (TheStreet) -- CorMedix (CRMD) shares are up 5.58% to $5.03 in afternoon trading on Wednesday after the the company announced that it received positive regulatory feedback for its second clinical trial of Neutrolin from the Food and Drug Administration.
The FDA sees Nuetrolin as a potentially good candidate as a catheter lock solution in oncology patients who require total parenteral, or other than through the digestive tract, nutrition.
"CorMedix is thankful for the valuable feedback provided by the FDA, and we are encouraged by their continued enthusiasm and support of Neutrolin. We are optimistic that this trial will further our efforts to bring Neutrolin to market in the United States so that more patients can benefit from its use," said CEO Randy Milby.
TheStreet Ratings team rates CORMEDIX INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:
- You can view the full analysis from the report here: CRMD Ratings Report